Loading stock data…
$16.17-0.48 (-2.88%)
Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. in the Healthcare sector is trading at $16.17 with a market capitalization of $1.6B. Wall Street consensus targets $27.76 (21 analysts), implying a +71.7% move over the next 12 months. The stock is currently 45% below its 52-week high of $29.65, remaining 15.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $254.56M↑ | $247.22M↓ | $290.38M↑ | $249.25M↑ | $240.68M |
| Gross Profit | $144.78M↑ | $136.79M↓ | $167.46M↑ | $134.29M↑ | $125.86M |
| Operating Income | -$13.79M↑ | -$17.43M↓ | $8.29M↑ | -$22.86M↑ | -$31.86M |
| Net Income | -$21.17M↓ | -$20.39M↓ | -$589,000↑ | -$21.16M↑ | -$52.40M |
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin ...